The tumor-bearing mice were treated with control siRNA-DOPC, EphA2-siRNA-DOPC, EphA2+FAK-siRNA-DOPC and EphA2+Src-siRNA-DOPC intraperitoneally twice in a week at a dose of 5 μg siRNA/200 μL suspensions. The gene discussed is SRC; the disease is neoplasm.